FUSION MEDICAL TECHNOLOGIES RAPISEAL 510(k) FILED IN APRIL, FIRM SAYS IN PROSPECTUS; 96% EFFECTIVENESS RATE IN LUNG RESECTION PATIENTS SHOWN IN CLINICALS
This article was originally published in The Gray Sheet
Executive Summary
Fusion Medical Technologies' RapiSeal collagen-based biodegradable patch successfully treated 96% of air leaks in a study of cancer patients who were undergoing lung resection surgery, the Mountain View, California-based firm says in a preliminary prospectus for its initial public offering.
You may also be interested in...
Surgical Sealants, Inc. Hoping To Debut SurgiSeal Vascular Sealant In 2000
Development stage Surgical Sealants, Inc. is currently conducting clinical trials of its collagen-based SurgiSeal vascular sealant and expects to submit a 510(k) to FDA by year-end.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.